axxonis Pharma AG

Axxonis Pharma AG, Berlin, is a pharmaceutical company specialized on CNS products. Axxonis is developing a portfolio of internally discovered or licensed product candidates to improve the therapeutic benefits of existing drugs and develop the products for indications of higher value. Axxonis’ most advanced product candidate, the lisuride patch, is the subject of a Phase III clinical program for the treatment of RLS which has now been completed successfully. Axxonis has also reported positive results from a Phase III clinical trial of transdermal lisuride (as separate brand) in patients with advanced Parkinson’s Disease. Axxonis is also committed to the development and marketing of the parenteral application form of lisuride for continuous dopaminergic stimulation (CDS).